Jul. 27 at 3:11 PM
🔥
$RMTG Keeps Delivering — Growth is Compounding.
⚡ Regenerative Medical Technologies Group (OTC:
$RMTG) just dropped a string of powerful catalysts that scream growth, execution, and long-term upside in the booming regenerative medicine space.
Q1 2026 results crushed it:
💵 Revenue surged 93% YoY to
$2.64 million
💵 Gross profit jumped 87%
💵 Operating income climbed 70% to nearly
$230K
💥 Training revenue (ISSCA) exploded 433%, while Cellgenic product supplies more than doubled. The Turnkey membership model is clearly firing on all cylinders — locking in recurring revenue and exclusive product pull-through across a 30+ country network.
ℹ But the real story is the strategic build-out:
Cellgenic just planted its flag in Argentina, creating a major commercial hub for biologics distribution, physician education, and regional expansion across Latin America. CEO David Christensen called it a cornerstone for years of growth.
ISSCA Mobile App is live — digitizing a hard-to-replicate global physician network and turning one-time training into always-on engagement.
ℹ ISSCA AI™ Clinical Intelligence Platform just launched — bringing AI-assisted intake, protocol support, predictive modeling, and workflow tools to regenerative and longevity clinics. This layers scalable tech on top of the education and biologics engine.
$RMTG is methodically assembling a fully integrated ecosystem: physician education + biologics commercialization + digital infrastructure + AI. Few players in regenerative medicine are positioned to do this at scale.
📈 With record financials, expanding margins, a growing recurring-revenue base, and aggressive international + tech expansion,
$RMTG is writing a compelling growth story for 2026 and beyond.
The regenerative medicine wave is here.
$RMTG is riding it hard.
Website:
https://www.regenmedtechgroup.com/ir
